What we achieved in 2025, together
Date
Research news
Date
Results show that atomoxetine, a drug used to treat attention deficit hyperactivity disorder (ADHD), could improve thinking and impulsiveness in Parkinson’s.
Date
Researchers in the United States have shown that a compound found in fruit - farnesol - has the potential to play a protective role to dopamine-producing brain cells.
Date
New research has been published that sheds an important light on how the production of a key protein in the brain is controlled This could pave the way for new treatments for a wide range of neurological conditions.
Date
Research shows it’s possible to identify Parkinson’s based on compounds found on the surface of skin. The findings offer hope that the condition could be diagnosed through a simple swab test.
Date
The earlier groundbreaking clinical trial proved inconclusive. So we’re launching a new company tasked with planning a possible new trial.
Date
New research has advanced our understanding of a protein called alpha-synuclein, which is believed to play a central role in damaging brain cells in Parkinson’s.
Date
Scientists in the UK have uncovered evidence that simple vision tests can predict who will develop Parkinson's dementia. And the evidence shows that a loss of wiring in the brain may be the cause.
Date
We’ve partnered with Alzheimer’s Society and University College London Hospitals (UCLH) Biomedical Research Centre. Together, we’ve developed a new resource to help lab-based researchers with patient and public involvement (PPI).
Date
Our recent survey has found that nearly three quarters (74%) of people on Parkinson's medication experience 'wearing off', when symptoms including pain, stiffness and tremors become worse between doses.
Date
Parkinson’s UK is joining forces with US charity The Michael J. Fox Foundation and biopharma company Neurolixis to fund a £1.5m clinical trial of an exciting new drug to combat dyskinesia in people with Parkinson’s.